New insider activity at Quest Diagnostics ( (DGX) ) has taken place on October 24, 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Director Gary Pfeiffer recently sold 1,482 shares of Quest Diagnostics stock, amounting to a total transaction value of $270,316.
Recent Updates on DGX stock
Quest Diagnostics reported strong third-quarter financial results for 2025, with a 13.1% increase in revenue to $2.82 billion and an 8.5% rise in diluted earnings per share. The company’s strategic initiatives, including a joint venture with Corewell Health and acquisitions from Fresenius Medical Care, contributed to this growth. The positive performance led to an upward revision of its full-year revenue guidance to $10.96 billion-$11.00 billion. Analysts raised their price targets for Quest Diagnostics, driven by the company’s robust earnings, strategic partnerships, and expansion in consumer health collaborations, which underscore its growth potential in the healthcare sector.
Spark’s Take on DGX Stock
According to Spark, TipRanks’ AI Analyst, DGX is a Outperform.
Quest Diagnostics’ overall stock score reflects its strong financial performance, positive earnings call, and solid technical indicators. The company’s strategic acquisitions and operational improvements have bolstered growth, while its valuation remains fair. However, mixed revenue growth and potential risks from moderate leverage and external challenges like tariffs and legislative changes should be monitored.
To see Spark’s full report on DGX stock, click here.
More about Quest Diagnostics
YTD Price Performance: 23.75%
Average Trading Volume: 904,356
Technical Sentiment Signal: Buy
Current Market Cap: $20.15B